6. Parkinson disease
2,123 clinical trials,   2,046 drugs   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
17 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04117178
(ClinicalTrials.gov)
February 4, 202030/9/2019Monitoring Anti-Dementia Drugs by Serum LevelsMonitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title)Dementia;Dementia With Lewy Bodies;Dementia in Parkinsons Disease;Dementia Alzheimers;Alzheimer DiseaseDrug: Donepezil;Drug: Memantine;Diagnostic Test: Measurement of serum level of anti-dementia drugZealand University HospitalEpilepsihospitalet FiladelfiaRecruiting18 YearsN/AAll110Phase 4Denmark
2NCT03858270
(ClinicalTrials.gov)
April 1, 20192/10/2018Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, MemantineInhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, MemantineParkinson DiseaseDrug: Memantine;Other: PlaceboWayne State UniversityNULLRecruiting45 Years85 YearsAll50Phase 3United States
3EUCTR2017-002707-10-DK
(EUCTR)
10/04/201803/11/2017Measurements of drug concentration in the blood for anti-dementia drugs, in order to improve efficacy and reduce side-effectsSerum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance Dementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies
MedDRA version: 20.0;Level: PT;Classification code 10012271;Term: Dementia Alzheimer's type;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10075174;Term: Mixed dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Memantin Orion
INN or Proposed INN: MEMANTINE
Product Name: Donepezil Sandoz
Product Code: 25330
INN or Proposed INN: DONEPEZIL
Regional Dementia Research Centre, Dept of NeurologyNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
110Phase 4Denmark
4JPRN-UMIN000010596
2013/05/0101/05/2013Randomized crossover trial comparing memantine or amantadine for Parkinson's disease with motor fluctuations in Juntendo Parkinson's diseaseMemantine preceding arm
Titrate the memantine, administered for 3 months. And tapering memantine and amantadine titrate the dose for 3 months.

Amantadine preceding arm
Titrate the amantadine, administered for 3 months. And tapering amantadine and memantine titrate the dose for 3 months.
Department of Neurology, Juntendo University School of MedicineNULLComplete: follow-up complete20years-oldNot applicableMale40Not selectedJapan
5NCT01108029
(ClinicalTrials.gov)
October 200920/7/2009Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's DiseaseStudy of Memantine to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Monocentric TrialParkinson's Disease;Gait Disorders, NeurologicDrug: memantine;Drug: placeboUniversity Hospital, LilleNULLCompleted30 Years80 YearsBoth28Phase 4France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2005-002038-36-GR
(EUCTR)
27/02/200709/10/2006A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesA randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies Patients with Parkinson’s disease dementia or dementia with Lewy Bodies
MedDRA version: 8.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
H. Lundbeck A/SNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Germany;United Kingdom;France;Spain;Italy;Greece;Austria
7NCT00855686
(ClinicalTrials.gov)
January 20073/3/2009Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy BodiesA Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy BodiesParkinson's Disease Dementia;Dementia With Lewy BodiesDrug: Memantine;Drug: PlaceboH. Lundbeck A/SNULLCompleted50 YearsN/ABoth199Phase 4Germany
8EUCTR2005-002038-36-FR
(EUCTR)
01/12/200624/08/2010A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesA randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies Patients with Parkinson’s disease dementia or dementia with Lewy BodiesTrade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
H. Lundbeck A/SNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Germany;United Kingdom;France;Spain;Italy;Greece;Austria
9EUCTR2005-002038-36-DE
(EUCTR)
29/11/200619/01/2007A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesA randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies Patients with Parkinson’s disease dementia or dementia with Lewy BodiesTrade Name: Ebixa
Product Name: Memantine
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Product Name: Memantine
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Memantine
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Product Name: Memantine
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
H. Lundbeck A/SNULLNot RecruitingFemale: yes
Male: yes
200United Kingdom;Germany;France;Spain;Italy;Greece;Austria
10EUCTR2005-002038-36-GB
(EUCTR)
31/10/200609/10/2006A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesA randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies Patients with Parkinson’s disease dementia or dementia with Lewy Bodies
MedDRA version: 8.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease
H. Lundbeck A/SNULLNot Recruiting Female: yes
Male: yes
200Phase 4France;Greece;Spain;Austria;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2005-002038-36-AT
(EUCTR)
22/09/200609/10/2006A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesA randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies Patients with Parkinson’s disease dementia or dementia with Lewy BodiesTrade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Trade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
H. Lundbeck A/SNULLNot RecruitingFemale: yes
Male: yes
200Germany;United Kingdom;France;Spain;Italy;Greece;Austria
12NCT00646204
(ClinicalTrials.gov)
April 200628/12/2007Namenda (Memantine) for Non-Motor Symptoms in Parkinson's DiseaseA 16 WEEK, INVESTIGATOR-INITIATED, SINGLE-CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF NAMENDA® (MEMANTINE HCL) FOR NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASEParkinson's DiseaseDrug: Memantine;Drug: placeboBaylor College of MedicineForest LaboratoriesCompleted18 Years80 YearsBoth40Phase 4United States
13NCT00294554
(ClinicalTrials.gov)
April 200621/2/2006Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and DementiaDouble-Blind Placebo-Controlled Trial of Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and DementiaParkinson's Disease;Cognitive Impairment;DementiaDrug: Memantine;Drug: Placebo Oral TabletJohns Hopkins UniversityForest LaboratoriesCompleted50 YearsN/AAll20N/AUnited States
14EUCTR2005-004109-27-SE
(EUCTR)
24/03/200624/01/2006A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies - MEMDLBPDDA double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies - MEMDLBPDD Parkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia (PDD). The brain changes and clinical presentations of PDD and DLB are similar. The clinical characteristics are cognitive impairment with pronounced visuospatial and executive impairment, visual hallucinations, parkinsonism, fluctuations in cognition and REM sleep disorder.Trade Name: Ebixa
Product Name: Ebixa
Neuropsychiatric clinicNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Sweden
15NCT00630500
(ClinicalTrials.gov)
February 200627/2/2008Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy BodiesDementia Associated With Parkinson's Disease;Dementia With Lewy BodiesDrug: Memantine;Drug: PlaceboHelse Stavanger HFKing's College London;Lund UniversityCompletedN/AN/ABoth75Phase 2Norway;Sweden;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2004-004139-74-DK
(EUCTR)
20/04/200522/03/2005Parkinson’s Disease: PET scan and evaluation of memantines pharmacological effect.(Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/AParkinson’s Disease: PET scan and evaluation of memantines pharmacological effect.(Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/A Parkinson's DiseaseTrade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: memantine
Neurologisk afdeling FNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Phase 2Denmark
17NCT00375778
(ClinicalTrials.gov)
April 200512/9/2006Parkinson's Disease Evaluated by PET and the Effect of MemantineParkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist MemantineParkinson's DiseaseDrug: memantine (drug)University of AarhusLundbeck FoundationCompleted50 Years70 YearsBoth12N/ADenmark